{
    "nct_id": "NCT06307795",
    "official_title": "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1\n* Life expectancy ≥ 12 weeks\n* Measurable disease per RECIST v1.1\n* Adequate organ and marrow function as defined in the protocol\n* With a pathogenetic MET alteration (including MET mutation, MET amplification, MET overexpression, MET fusion)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active infection including tuberculosis and HBV, HCV or HIV\n* Known active or untreated CNS metastases\n* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression\n* Participants with serious cardiovascular or cerebrovascular diseases",
    "miscellaneous_criteria": ""
}